EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Evaluation of new treatments for benign prostatic obstruction: ICI‐RS 2023

Hashim Hashim, Tufan Tarcan, Omer Acar, Sachin Malde, Alan Wein, Paul Abrams

Neurourology and Urodynamics · 2024

DOI: 10.1002/nau.25345 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, 2024. Verfasst von Hashim Hashim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Urological Institute, Bristol, UK. Hauptthemen laut MEDLINE: Prostatic Hyperplasia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To address how invasive therapies for benign prostatic obstruction (BPO) have been evaluated, what their effect is on BPO, if they can prevent progression to BPO and how new therapies need to be evaluated before implementation into clinical practice.

Methods

The think tank conducted a literature review and looked at the previous and current American Urological Association, European Association of Urology and the International Consultation on Urological Diseases guidelines to see what procedures have been used to treat BPO. They then assessed whether trials have been conducted before implementation of the procedures and whether they have been compared to a “gold” standard treatment. The use of urodynamics has also been addressed in the think tank in relation the clinical trials as well as terminology.

Results

Guidelines vary in the use of terminology when it comes to BPO with some continuing to use the term benign prostatic hyperplasia (BPH). There are several procedures for example, TUNA, which have become obsolete although continues to be mentioned in the guidelines until recently. Majority of procedures have been introduced without comparing to “gold” standard treatment and without any long‐term data. There continues to be many unknowns with regard to the success of some of the BPO procedures and why some of the adverse events develop.

Conclusion

There needs to be more robust long‐term clinical trials conducted of new BPO therapies, with men who have both lower urinary tract symptoms and urinary retention, before introduction into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaHumansMalePractice Guidelines as TopicUrodynamicsTreatment OutcomeUrinary Bladder Neck ObstructionLower Urinary Tract Symptoms

Stichwörter der Autor:innen

HoLEPTURPbenign prostatic hyperplasiabenign prostatic obstructionurodynamics

Autor:innen und Institutionen

  • Bristol Urological Institute, Bristol, UK.
  • Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.
  • Department of Urology, Koç University School of Medicine, Istanbul, Turkey.
  • Department of Urology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Desai Sethi Institute of Urology, University of Miami Miller School of Medicine, Miami, Florida, USA.

Zitieren

APA

Hashim, H., Tarcan, T., Acar, O., Malde, S., Wein, A., & Abrams, P. (2024). Evaluation of new treatments for benign prostatic obstruction: ICI‐RS 2023. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25345

Vancouver

Hashim H, Tarcan T, Acar O, Malde S, Wein A, Abrams P. Evaluation of new treatments for benign prostatic obstruction: ICI‐RS 2023. Neurourology and Urodynamics. 2024. doi:10.1002/nau.25345

BibTeX
@article{Hashim2024,
  author = {Hashim, Hashim and Tarcan, Tufan and Acar, Omer and Malde, Sachin and Wein, Alan and Abrams, Paul},
  title = {Evaluation of new treatments for benign prostatic obstruction: ICI‐RS 2023},
  journal = {Neurourology and Urodynamics},
  year = {2024},
  doi = {10.1002/nau.25345}
}
Kostenlos starten →